Ítem
Desconocido

Clinical Characteristics and Outcomes of Adults with Budd-Chiari Syndrome: A Single-Center Experience in Colombia

Mostrar el registro sencillo de la publicación
dc.contributor.advisorBeltrán Galvis, Oscar Alfredo
dc.contributor.advisorDurán Torres, Carlos Felipe
dc.contributor.otherSalinas, Diana Carolina
dc.contributor.otherTorres, Cristina
dc.contributor.otherGarzón, Martín
dc.contributor.otherLópez Panqueva, Rocío
dc.contributor.otherPérez, Juan Manuel
dc.contributor.otherVarón, Adriana
dc.contributor.otherHernández-Cely, Geovanny
dc.contributor.otherDurán Torres, Felipe
dc.creatorMorales Cruz, Ximena del Pilar
dc.creator.degreeEspecialista en Hepatología
dc.creator.degreeLevelEspecialización
dc.date.accessioned2026-02-11T12:25:52Z
dc.date.available2026-02-11T12:25:52Z
dc.date.created2026-02-02
dc.descriptionIntroducción: El síndrome de Budd-Chiari se define como la obstrucción del flujo venoso hepático. En Colombia existe evidencia limitada sobre la caracterización de estos pacientes. Este estudio tuvo como objetivo describir las características clínicas, el manejo y la supervivencia de los pacientes diagnosticados con síndrome de Budd-Chiari en un centro de referencia en hepatología en Colombia entre 2010 y 2022. Métodos: Estudio longitudinal, descriptivo y retrospectivo de una cohorte de pacientes adultos con síndrome de Budd-Chiari atendidos en un centro de hepatología en Colombia desde enero de 2010 hasta enero de 2022. Resultados: Se incluyeron 31 pacientes con diagnóstico de síndrome de Budd-Chiari. El 61,3% (n = 19) eran mujeres. La mediana de edad fue de 28 años [rango intercuartílico (RIC) 23–38]. Las trombofilias adquiridas fueron el principal factor de riesgo (58,1%; n = 18), principalmente secundarias al síndrome antifosfolípido (55,5%; n = 10). La manifestación clínica principal fue la ascitis en el 87,1% (n = 27). Al momento del diagnóstico, el 74,2% (n = 23) se encontraba en fase crónica y 5 pacientes tenían cirrosis documentada por biopsia. El puntaje de Rotterdam fue clase II (pronóstico intermedio) en el 48,3% (n = 14). El 86% (n = 25) de los pacientes recibió tratamiento con anticoagulación. Cinco pacientes (16,1%) fueron sometidos a derivación portosistémica intrahepática transyugular (TIPS). Once pacientes fallecieron (35,5%), con una mediana de supervivencia desde el diagnóstico hasta la muerte de 337,1 días (RIC 46,5–647,5). Conclusión: El síndrome de Budd-Chiari es una enfermedad poco caracterizada en la población colombiana. Este estudio muestra que las trombofilias adquiridas son el principal factor de riesgo asociado con esta condición médica en esta población, con características clínicas y tasas de mortalidad similares a las reportadas en la literatura.
dc.description.abstractIntroduction: Budd-Chiari syndrome is defined as the obstruction of hepatic venous flow. Limited evidence exists in Colombia regarding the characterization of these patients. This study aimed to describe the clinical characteristics, management, and survival of patients diagnosed with Budd-Chiari syndrome in a Colombian hepatology referral center from 2010 to 2022. Methods: This is a descriptive retrospective longitudinal study of a cohort of patients with Budd-Chiari syndrome in adult patients diagnosed with Budd-Chiari syndrome in a Colombian hepatology center from January 2010 to January 2022. Results: 31 patients diagnosed with Budd-Chiari syndrome were included. Of the patients, 61.3% (n = 19) were female. The median age was 28 years [interquartile range (IQR) 23–38]. Acquired thrombophilias were the main risk factor (58.1%, n = 18), mainly secondary to antiphospholipid syndrome (55.5%, n = 10). The primary clinical manifestation presented was ascites 87.1% (n = 27). At diagnosis, 74.2% (n = 23) were in a chronic course, and 5 patients had cirrhosis documented by biopsy. The Rotterdam score was class II (intermediate prognosis) in 48.3% (n = 14). Of the patients, 86% (n = 25) had anticoagulation therapy. Five patients (16.1%) underwent transjugular intrahepatic portosystemic shunt. Eleven patients died (35.5%), with a median survival time from diagnosis to death of 337.1 days (IQR 46.5–647.5). Conclusion: Budd-Chiari syndrome is a poorly characterized disease in the Colombian population. This study shows that acquired thrombophilias are the leading risk factor associated with this medical condition in this population, with clinical features and mortality rates similar to those reported in the literature.
dc.format.extent18 pp
dc.format.mimetypeapplication/pdf
dc.identifier.doihttps://doi.org/10.48713/10336_47523
dc.identifier.urihttps://repository.urosario.edu.co/handle/10336/47523
dc.language.isoeng
dc.publisherUniversidad del Rosario
dc.publisher.departmentEscuela de Medicina y Ciencias de la Salud-Especializaciones Médico Quirúrgicas
dc.publisher.programEspecialización en Hepatología
dc.relation.relatedhttps://doi.org/10.1159/000547006
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 International*
dc.rights.accesRightsinfo:eu-repo/semantics/closedAccess
dc.rights.accesoBloqueado (Texto referencial)
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.source.bibliographicCitationEuropean Association for the Study of the Liver. Electronic address: easloffice@easloffice.eu EASL clinical practice guidelines: vascular diseases of the liver. J Hepatol. 2016; 64(1):179–202. https://doi.org/10.1016/j. jhep.2015.07.040
dc.source.bibliographicCitationValla DC. Budd–Chiari syndrome/hepatic venous outflow tract obstruction. Hepatol Int. 2018;12(Suppl 1):168–80. https://doi. org/10.1007/s12072-017-9810-5
dc.source.bibliographicCitationHaque LYK, Lim JK. Budd-Chiari syndrome: an uncommon cause of chronic liver disease that cannot be missed. Clin Liver Dis. 2020; 24(3):453–81. https://doi.org/10.1016/j.cld. 2020.04.012
dc.source.bibliographicCitationAgeno W, Dentali F, Pomero F, Fenoglio L, Squizzato A, Pagani G, et al. Incidence rates and case fatality rates of portal vein thrombosis and Budd-Chiari Syndrome. Thromb Haemost. 2017;117(4):794–800. https://doi.org/10.1160/TH16-10-0781
dc.source.bibliographicCitationSimonetto DA, Singal AK, Garcia-Tsao G, Caldwell SH, Ahn J, Kamath PS. ACG clinical guideline: disorders of the hepatic and mesenteric circulation. Am J Gastroenterol. 2020; 115(1):18–40. https://doi.org/10.14309/ajg. 0000000000000486
dc.source.bibliographicCitationGarcia-Pagán JC, Valla DC. Primary budd–chiari syndrome. N Engl J Med Overseas Ed. 2023;388(14):1307–16. https:// doi.org/10.1056/NEJMra2207738
dc.source.bibliographicCitationMurad SD, Plessier A, Hernandez-Guerra M, Fabris F, Eapen CE, Bahr MJ, et al. Etiology, Management, and Outcome of the Budd- Chiari Syndrome:11.
dc.source.bibliographicCitationRajani R, Melin T, Björnsson E, Broomé U, Sangfelt P, Danielsson A, et al. Budd-Chiari syndrome in Sweden: epidemiology, clinical characteristics and survival - an 18-year experience. Liver Int. 2009;29(2):253–9. https://doi.org/10.1111/j.1478-3231.2008. 01838.x
dc.source.bibliographicCitationQi X, Ren W, Wang Y, Guo X, Fan D. Survival and prognostic indicators of Budd–Chiari syndrome: a systematic review of 79 studies. Expert Rev Gastroenterol Hepatol [Internet]. 2015;9(6):865–75. https://doi.org/10.1586/17474124.2015. 1024224
dc.source.bibliographicCitationZhang H, Morrison S, Tang YW. Multiplex polymerase chain reaction tests for detection of pathogens associated with gastroenteritis. Clin Lab Med. 2015;35(2):461–86. https:// doi.org/10.1016/j.cll.2015.02.006
dc.source.bibliographicCitationZhang W, Qi X, Zhang X, Su H, Zhong H, Shi J, et al. Budd-Chiari syndrome in China: a systematic analysis of epidemiological features based on the Chinese Literature Survey. Gastroenterol Res Pract. 2015;2015:1–8. https://doi.org/10.1155/ 2015/738548
dc.source.bibliographicCitationKi M, Choi HY, Kim KA, Kim BH, Jang ES, Jeong SH. Incidence, prevalence and complications of Budd-Chiari syndrome in South Korea: a nationwide, population-based study. Liver Int. 2016;36(7):1067–73. https://doi.org/10.1111/liv.13008
dc.source.bibliographicCitationMuñoz MOG, Vergara Cadavid JA, Cajiao Castro L, Marín Zuluaga JI, Restrepo Gutiérrez JC, Santos Sánchez OM. Síndrome de Budd-Chiari: etiología, manejo y resultados en una cohorte de 35 pacientes del Hospital Pablo Tobón Uribe. Rev Colomb Gastroenterol [Internet]. 2020;35(3):280–6. Available from: https://revistagastrocol.com/ index.php/rcg/article/view/431
dc.source.bibliographicCitationMartens P, Nevens F. Budd-Chiari syndrome. United Eur Gastroenterol J [Internet]. 2015; 3(6):489–500. https://doi.org/10.1177/ 2050640615582293
dc.source.bibliographicCitationSakr M, Abdelhakam SM, Elsayed SA, Allam EH, Farid AM, Abdelmoaty W, et al. Validation of prognostic indices in Egyptian Budd-Chiari syndrome patients: a single- center study. World J Gastroenterol. 2017; 23(4):629–37. https://doi.org/10.3748/wjg. v23.i4.629
dc.source.bibliographicCitationDongelmans E, Erler N, Adam R, Nadalin S, Karam V, Yilmaz S, et al. Recent outcomes of liver transplantation for Budd-Chiari syndrome: a study of the European Liver Transplant Registry (ELTR) and affiliated centers. Hepatology. 2024;80(1):136–51. https://doi.org/10.1097/HEP. 0000000000000778
dc.source.bibliographicCitationQi X, Ren WY, GuoFan XD, Guo X, Fan D. Survival and prognostic indicators of Budd–Chiari syndrome: a systematic review of 79 studies. Expert Rev Gastroenterol Hepatol. 2015;9(6):865–75.
dc.source.bibliographicCitationPavri TM, Herbst A, Reddy R, Forde KA. Budd-Chiari syndrome: a single-center experience. World J Gastroenterol. 2014; 20(43):16236–44. https://doi.org/10.3748/ wjg.v20.i43.16236
dc.source.bibliographicCitationSeijo S, Plessier A, Hoekstra J, Dell’era A, Mandair D, Rifai K, et al. Good long-term outcome of Budd-Chiari syndrome with a step-wise management. Hepatology. 2013; 57(5):1962–8. https://doi.org/10.1002/hep. 26306
dc.source.instnameinstname:Universidad del Rosario
dc.source.reponamereponame:Repositorio Institucional EdocUR
dc.subjectSíndrome de Budd-Chiari
dc.subjectTrombosis venosa
dc.subjectCirrosis
dc.subjectTrasplante hepático
dc.subjectDerivación portosistémica intrahepática transyugular (TIPS)
dc.subject.keywordBudd-Chiari syndrome
dc.subject.keywordVein thrombosis
dc.subject.keywordCirrhosis
dc.subject.keywordLiver transplant
dc.subject.keywordTransjugular intrahepatic portosystemic shunt
dc.titleClinical Characteristics and Outcomes of Adults with Budd-Chiari Syndrome: A Single-Center Experience in Colombia
dc.title.TranslatedTitleCaracterísticas clínicas y desenlaces de adultos con síndrome de Budd-Chiari un un centro de experiencia en Colombia
dc.title.alternativeCaracterización de Síndrome de Budd-Chiari en Colombia
dc.typemasterThesis
dc.type.hasVersioninfo:eu-repo/semantics/acceptedVersion
dc.type.spaTrabajo de grado
local.department.reportEscuela de Medicina y Ciencias de la Salud
local.regionesBogotá
Archivos
Bloque original
Mostrando1 - 1 de 1
Miniatura
Nombre:
Clinical_Characteristics_and_Outcomes_of_Adults.pdf
Tamaño:
254.16 KB
Formato:
Adobe Portable Document Format
Descripción:
Descargar
Colecciones
Especialización en Hepatología